N8-GP: A new extended half-life recombinant factor VIII product for hemophilia A

被引：2
|
作者：
Chowdary, Pratima [1 ]
机构：
[1] Royal Free Hosp, Katharine Dormandy Haemophilia & Thrombosis Ctr, Pond St, London NW3 2QG, England
来源：
JOURNAL OF THROMBOSIS AND HAEMOSTASIS | 2020年 / 18卷
关键词：
D O I：
10.1111/jth.14966
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：3 / 4
页数：2
相关论文
共 50 条
  • [31] Bleeding Patterns During Prophylaxis with a Full-Length Pegylated Recombinant Factor VIII (Bax 855) with Extended Half-Life in Hemophilia A
    Konkle, B. A.
    Stasyshn, O.
    Wynn, T. T.
    Manco-Johnson, M. J.
    Gruppo, R.
    Chowdary, P.
    Komrska, V.
    Griskevicius, L.
    Eyster, M. E.
    Chojnowski, K.
    Engl, W.
    Patrone, L.
    Abbuehl, B.
    HAEMOPHILIA, 2016, 22 : 99 - 100
  • [32] Course of target joint bleeding with prophylaxis of a pegylated full-length recombinant factor VIII with extended half-life in patients with hemophilia A
    Abbuehl, Brigitt
    Engl, Werner
    Patrone, Lisa
    Prener, Anne
    HAEMOPHILIA, 2016, 22 : 48 - 48
  • [33] HEAT INACTIVATION OF EXTENDED HALF-LIFE FACTOR VIII CONCENTRATES
    Fylling, Kara A.
    Tange, Julie I.
    Chen, Dong
    Pruthi, Rajiv K.
    AMERICAN JOURNAL OF HEMATOLOGY, 2018, 93 (09) : E20 - E20
  • [34] Heat inactivation of extended half-life factor VIII concentrates
    Fylling, Kara A.
    Tange, Julie I.
    Chen, Dong
    Pruthi, Rajiv K.
    HAEMOPHILIA, 2019, 25 (02) : E130 - E131
  • [35] Intravenous Administration of Recombinant Factor VIII Induces Immune Tolerance to Subcutaneous Turoctocog Alfa Pegol (SC N8-GP) in Humanized Hemophilia A Mice
    Reedtz-Runge, Stine Louise
    Weldingh, Karin
    Schultz, Heidi Schioler
    Millner, Anders Holm
    Rode, Frederik
    Wiinberg, Bo
    Kjelgaard-Hansen, Mads
    BLOOD, 2018, 132
  • [36] New and Emerging Agents for the Treatment of Hemophilia: Focus on Extended Half-Life Recombinant Clotting Proteins
    Ragni, Margaret V.
    DRUGS, 2015, 75 (14) : 1587 - 1600
  • [37] New and Emerging Agents for the Treatment of Hemophilia: Focus on Extended Half-Life Recombinant Clotting Proteins
    Margaret V. Ragni
    Drugs, 2015, 75 : 1587 - 1600
  • [38] Extended Half-Life of the Double-Chain Recombinant Factor VIII-Fc Fusion Protein (FRSW107) in Hemophilia a Patients
    Xue, Feng
    Sun, Jing
    Chen, Yun
    Zhang, Xinsheng
    Sun, Haiyan
    Wang, Yali
    Yang, Renchi
    BLOOD, 2019, 134
  • [39] New recombinant factor VIII approved - Bayer product is for hemophilia A
    不详
    BIOTECHNOLOGY LAW REPORT, 2001, 20 (01) : 16 - 16
  • [40] COMPARISON OF REAL-WORLD DOSE AND CONSUMPTION OF TWO EXTENDED HALF-LIFE RECOMBINANT FACTOR VIII PRODUCTS FOR THE TREATMENT OF HEMOPHILIA A IN THE UNITED STATES
    Wu, Y.
    Sun, S.
    Fan, T.
    VALUE IN HEALTH, 2019, 22 : S871 - S871
12345